| Drug Discovery & Development | Daiichi Sankyo Enters Licensing Agreement with Boston Pharmaceuticals for Highly Selective RET Inhibitor for Solid ... Drug Discovery & Development RET rearrangements and activating mutations are associated with several types of cancer, including non-small cell lung cancer, colorectal cancer and thyroid cancer.1,2,3. Under the terms of the agreement, Daiichi Sankyo grants Boston Pharmaceuticals ... |
from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2gpFquW
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,